Comments
Loading...

Humacyte

HUMANASDAQ
$7.55
-0.19-2.39%
At Close: -
$7.60
0.050.66%
After Hours: 7:59 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$17.00
Lowest Price Target1
$3.00
Consensus Price Target1
$9.88

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Humacyte (NASDAQ:HUMA) Stock, Analyst Ratings, Price Targets, Forecasts

Humacyte Inc has a consensus price target of $9.88 based on the ratings of 8 analysts. The high is $17 issued by Cowen & Co. on October 29, 2021. The low is $3 issued by Piper Sandler on November 10, 2023. The 3 most-recent analyst ratings were released by BTIG, Cantor Fitzgerald, and Benchmark on July 15, 2024, July 2, 2024, and July 2, 2024, respectively. With an average price target of $11 between BTIG, Cantor Fitzgerald, and Benchmark, there's an implied 44.74% upside for Humacyte Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Mar
1
Apr
0
0
0
0
May
1
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

BTIG
Cantor Fitzgerald
Benchmark
Piper Sandler
HC Wainwright & Co.

1calculated from analyst ratings

Analyst Ratings for Humacyte

Buy NowGet Alert
07/15/2024Buy Now44.74%BTIG
Ryan Zimmerman
$8 → $11MaintainsBuyGet Alert
07/02/2024Buy Now-7.89%Cantor Fitzgerald
Kristen Kluska
$7 → $7ReiteratesOverweight → OverweightGet Alert
07/02/2024Buy Now97.37%Benchmark
Bruce Jackson
$15 → $15ReiteratesBuy → BuyGet Alert
05/24/2024Buy Now97.37%Benchmark
Bruce Jackson
→ $15ReiteratesBuy → BuyGet Alert
05/13/2024Buy Now97.37%Benchmark
Bruce Jackson
→ $15ReiteratesBuy → BuyGet Alert
04/01/2024Buy Now-7.89%Cantor Fitzgerald
Kristen Kluska
→ $7ReiteratesOverweight → OverweightGet Alert
03/26/2024Buy Now-47.37%Piper Sandler
Allison Bratzel
$4 → $4MaintainsNeutralGet Alert
03/25/2024Buy Now97.37%Benchmark
Bruce Jackson
→ $15ReiteratesBuy → BuyGet Alert
03/08/2024Buy Now-47.37%Piper Sandler
Allison Bratzel
$3 → $4MaintainsNeutralGet Alert
12/27/2023Buy Now97.37%Benchmark
Bruce Jackson
$16 → $15MaintainsBuyGet Alert
12/11/2023Buy Now-21.05%HC Wainwright & Co.
Vernon Bernardino
→ $6Initiates → BuyGet Alert
11/10/2023Buy Now-60.53%Piper Sandler
Matt O'Brien
$3.5 → $3MaintainsNeutralGet Alert
09/21/2023Buy Now-7.89%Cantor Fitzgerald
Kristen Kluska
→ $7ReiteratesOverweight → OverweightGet Alert
08/31/2023Buy Now-21.05%Cantor Fitzgerald
Kristen Kluska
→ $6ReiteratesOverweight → OverweightGet Alert
08/24/2023Buy Now-21.05%Cantor Fitzgerald
Kristen Kluska
→ $6ReiteratesOverweight → OverweightGet Alert
08/15/2023Buy Now110.53%Benchmark
Bruce Jackson
→ $16ReiteratesBuy → BuyGet Alert
06/22/2023Buy Now-21.05%Cantor Fitzgerald
Kristen Kluska
→ $6Initiates → OverweightGet Alert
06/12/2023Buy Now110.53%Benchmark
Bruce Jackson
→ $16ReiteratesBuy → BuyGet Alert
03/27/2023Buy Now110.53%Benchmark
Bruce Jackson
→ $16Reiterates → BuyGet Alert
07/18/2022Buy Now31.58%BTIG
Ryan Zimmerman
$12 → $10MaintainsBuyGet Alert
10/29/2021Buy Now123.68%Cowen & Co.
Joshua Jennings
Initiates → OutperformGet Alert
09/24/2021Buy Now110.53%Oppenheimer
Suraj Kalia
Initiates → OutperformGet Alert
09/22/2021Buy Now150%BTIG
Ryan Zimmerman
Initiates → BuyGet Alert
09/16/2021Buy Now123.68%Piper Sandler
Matt O'Brien
Initiates → OverweightGet Alert

FAQ

Q

What is the target price for Humacyte (HUMA) stock?

A

The latest price target for Humacyte (NASDAQ:HUMA) was reported by BTIG on July 15, 2024. The analyst firm set a price target for $11.00 expecting HUMA to rise to within 12 months (a possible 44.74% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Humacyte (HUMA)?

A

The latest analyst rating for Humacyte (NASDAQ:HUMA) was provided by BTIG, and Humacyte maintained their buy rating.

Q

When was the last upgrade for Humacyte (HUMA)?

A

There is no last upgrade for Humacyte

Q

When was the last downgrade for Humacyte (HUMA)?

A

There is no last downgrade for Humacyte.

Q

When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on July 15, 2024 so you should expect the next rating to be made available sometime around July 15, 2025.

Q

Is the Analyst Rating Humacyte (HUMA) correct?

A

While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a maintained with a price target of $8.00 to $11.00. The current price Humacyte (HUMA) is trading at is $7.60, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch